Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.

Journal Article (Review)

Seven trials of new agents to treat type 2 diabetes (T2DM) have been performed to assess cardiovascular (CV) safety. A significant amount of information regarding the effects of drugs in three classes is available, with new data from multiple other trials expected shortly. This article provides a summary of recently completed trials.The dipeptidyl peptidase-4 inhibitors studied thus far do not alter the risk of major adverse CV events (MACE). Glucagon like peptide-1 receptor agonists liraglutide and semaglutide, and the sodium glucose cotransporter-2 inhibitor empagliflozin, significantly reduced the risk of MACE. Empagliflozin also decreased the risk of hospitalization for heart failure. Agents demonstrating a CV outcome benefit also improved parameters of renal function. Several newer antihyperglycemic agents have been found to reduce the risk of important CV complications in high-risk patients with T2DM. Future trials are needed to assess the effects of additional drugs and the impact of therapy in lower risk patients and provide additional information regarding non-CV safety outcomes.

Full Text

Duke Authors

Cited Authors

  • Herbst, R; Bolton, W; Shariff, A; Green, JB

Published Date

  • September 2017

Published In

Volume / Issue

  • 17 / 9

Start / End Page

  • 67 -

PubMed ID

  • 28726152

Electronic International Standard Serial Number (EISSN)

  • 1539-0829

International Standard Serial Number (ISSN)

  • 1534-4827

Digital Object Identifier (DOI)

  • 10.1007/s11892-017-0898-8

Language

  • eng